Search

everythinglearnresearchcommunity

for

Search:↓

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user is considering creating an all-in-one topical solution for hair loss, combining 0.25mg finasteride, 5% minoxidil, and 5% RU58841. They are seeking advice on its feasibility and absorption.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Switching to a DIY topical finasteride solution using ethanol, glycerin, and distilled water instead of propylene glycol for a gentler application. Users report positive results with both DIY solutions and a low PG minoxidil and finasteride product from India.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.

User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.

The user is considering combining finasteride and minoxidil tablets into a topical solution that already includes Garnier Fructis stemoxydine and CB0103. They are seeking advice on whether this combination is effective and safe.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

A user preparing to start finasteride for hair loss wanted to check for any abnormal bloodwork related to hair loss. They shared their blood test results and learned from another user that their doctor prescribed finasteride without any preliminary tests.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The user is exploring alternatives to finasteride and dutasteride due to concerns about side effects, and is using rosemary and jojoba oil, ketoconazole, minoxidil, microneedling, multi-peptide serum, saw palmetto, and stinging nettle for hair loss. They are also considering CB 03 01 and spironolactone.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.